Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative bioavailability study of 480 mg versus 2 x 240 mg MK-8228 tablets in healthy women
NL-OMON40940Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of belzutifan in cytomegalovirus disease (CMV) (2 arms), sponsored by Merck & Co. Primary endpoints: AUC0-last, AUC0-inf and 1 more. Started Jun 2014; status: active, not recruiting.
02
Drugs
belzutifan
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on NL-OMON40940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40940.